Vincenzo Valentini1, Bengt Glimelius2, Karin Haustermans3, Corrie A M Marijnen4, Claus Rödel5, Maria Antonietta Gambacorta6, Petra G Boelens7, Cynthia Aristei8, Cornelis J H van de Velde7. 1. Department of Radiation Oncology, Cattedra di Radioterapia, Università Cattolica S. Cuore, Rome, Italy. 2. Department of Radiology, Oncology and Radiation Science, Uppsala University, Sweden. 3. Department of Radiation Oncology, University Hospitals Leuven Campus Gasthuisberg, Belgium. 4. Department of Clinical Oncology, Leiden University Medical Center, The Netherlands. 5. Radiation Oncology, University Hospital of Frankfurt, Germany. 6. Department of Radiation Oncology, Cattedra di Radioterapia, Università Cattolica S. Cuore, Rome, Italy. Electronic address: magambacorta@rm.unicatt.it. 7. Department of Surgery, Leiden University Medical Center, The Netherlands. 8. Radiation Oncology Section, Department of Surgery, Radiology and Dentistry, University of Perugia, Italy.
Abstract
BACKGROUND AND PURPOSE: Although rectal and colon cancer management has progressed greatly in the last few decades clinical outcomes still need to be optimized. Furthermore, consensus is required on several issues as some of the main international guidelines provide different recommendations. The European Registration of Cancer Care (EURECCA) drew up documents to standardize management and care in Europe and aid in decision-making. MATERIAL AND METHODS: In the present section the panel of experts reviews and discusses data from the literature on rectal cancer, focusing on recommendations for selecting between short-course radiotherapy (SCRT) and long-course radio-chemotherapy (LCRTCT) as preoperative treatment as well as on the controversies about adjuvant treatment in patients who had received a pre-operative treatment. RESULTS: The starting-point of the present EURECCA document is that adding SCRT or LCRTCT to TME improved loco-regional control but did not increase overall survival in any single trial which, in any case, had improved with the introduction of total mesorectal excision (TME) into clinical practice. Moderate consensus was achieved for cT3 anyNM0 disease. In this frame, agreement was reached on either SCRT followed by immediate surgery or LCRTCT with delayed surgery for mesorectal fascia (MRF) negative tumors at presentation. LCRTCT was recommended for tumor shrinkage in MRF+ at presentations but if patients were not candidates for chemotherapy, SCRT with delayed surgery is an option/alternative. LCRTCT was recommended for cT4 anycNM0. SCRT offers the advantages of less acute toxicity and lower costs, and LCRTCT tumor shrinkage and down-staging, with 13-36% pathological complete response (pCR) rates. To improve the efficacy of preoperative treatment both SCRT and LCRTCT have been, or are being, associated with diverse schedules of chemotherapy and even new targeted therapies but without any definitive evidence of benefit. Nowadays, standard treatment is fluoropyrimidine alone since alternative agents and regimens have not been shown to be more active, only more toxic. CONCLUSIONS: The EURECCA panel summarized available evidence in an attempt to reduce variance in rectal cancer management. This is expected to benefit patients. Results from ongoing randomized trials will help clarify some of the issues that are still under debate.
BACKGROUND AND PURPOSE: Although rectal and colon cancer management has progressed greatly in the last few decades clinical outcomes still need to be optimized. Furthermore, consensus is required on several issues as some of the main international guidelines provide different recommendations. The European Registration of Cancer Care (EURECCA) drew up documents to standardize management and care in Europe and aid in decision-making. MATERIAL AND METHODS: In the present section the panel of experts reviews and discusses data from the literature on rectal cancer, focusing on recommendations for selecting between short-course radiotherapy (SCRT) and long-course radio-chemotherapy (LCRTCT) as preoperative treatment as well as on the controversies about adjuvant treatment in patients who had received a pre-operative treatment. RESULTS: The starting-point of the present EURECCA document is that adding SCRT or LCRTCT to TME improved loco-regional control but did not increase overall survival in any single trial which, in any case, had improved with the introduction of total mesorectal excision (TME) into clinical practice. Moderate consensus was achieved for cT3 anyNM0 disease. In this frame, agreement was reached on either SCRT followed by immediate surgery or LCRTCT with delayed surgery for mesorectal fascia (MRF) negative tumors at presentation. LCRTCT was recommended for tumor shrinkage in MRF+ at presentations but if patients were not candidates for chemotherapy, SCRT with delayed surgery is an option/alternative. LCRTCT was recommended for cT4 anycNM0. SCRT offers the advantages of less acute toxicity and lower costs, and LCRTCT tumor shrinkage and down-staging, with 13-36% pathological complete response (pCR) rates. To improve the efficacy of preoperative treatment both SCRT and LCRTCT have been, or are being, associated with diverse schedules of chemotherapy and even new targeted therapies but without any definitive evidence of benefit. Nowadays, standard treatment is fluoropyrimidine alone since alternative agents and regimens have not been shown to be more active, only more toxic. CONCLUSIONS: The EURECCA panel summarized available evidence in an attempt to reduce variance in rectal cancer management. This is expected to benefit patients. Results from ongoing randomized trials will help clarify some of the issues that are still under debate.
Authors: Petra G Boelens; Claire Taylor; Geoffrey Henning; Perla J Marang-van de Mheen; Eloy Espin; Theo Wiggers; Jola Gore-Booth; Barbara Moss; Vincenzo Valentini; Cornelis J H van de Velde Journal: Patient Date: 2014 Impact factor: 3.883
Authors: Juan Pablo Ciria; Mikel Eguiguren; Sergio Cafiero; Intza Uranga; Ivan Diaz de Cerio; Arrate Querejeta; Jose Maria Urraca; Julian Minguez; Elena Guimon; Jose Ramón Puertolas Journal: Rep Pract Oncol Radiother Date: 2014-07-26
Authors: Ernst J Kuipers; William M Grady; David Lieberman; Thomas Seufferlein; Joseph J Sung; Petra G Boelens; Cornelis J H van de Velde; Toshiaki Watanabe Journal: Nat Rev Dis Primers Date: 2015-11-05 Impact factor: 52.329
Authors: Antonella Petrillo; Roberta Fusco; Vincenza Granata; Sergio Venanzio Setola; Mario Sansone; Daniela Rega; Paolo Delrio; Francesco Bianco; Giovanni Maria Romano; Fabiana Tatangelo; Antonio Avallone; Biagio Pecori Journal: Med Oncol Date: 2017-11-18 Impact factor: 3.064
Authors: Eun Kyoung Hong; Federica Landolfi; Francesca Castagnoli; Sae Jin Park; Judith Boot; Jose Van den Berg; Jeong Min Lee; Regina Beets-Tan Journal: Abdom Radiol (NY) Date: 2021-04-27